PENK and prostate carcinoma: For example, PENK promoter methylation was demonstrated in prostate cancer, breast cancer brain metastasis, and pulmonary adenocarcinoma, and as a potential methylation biomarker for colorectal, meningioma, and bladder cancer [48-53].